Daiichi Sankyo, AstraZeneca team with Summit to test Datroway-ivonescimab combo in cancer trials

By Public Technologies
  • Daiichi Sankyo entered a clinical trial collaboration with AstraZeneca, Summit Therapeutics to test Datroway with ivonescimab across solid tumors.
  • Program starts with a phase 3 trial in first-line triple-negative breast cancer, targeting expansion into other settings including lung cancer.
  • AstraZeneca or Daiichi Sankyo will sponsor the studies; all three companies will share trial costs.
  • Each partner keeps development and commercial rights to its own drug in the combination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.